[Therapy of refractory multiple myeloma. II. Therapy using high doses of alkylating cytostatic agents and radiotherapy in addition to interferon and bone marrow transplantation].
The author presents part II of his review on the treatment of refractory myeloma. Treatment with large doses of melphalane, 140 mg/m2, was associated with a high death rate and therefore it is used nowadays only in combination with autologous transplantation or treatment with leucocytic growth factors (GM-CSF and G-CSF). Medium doses of melphalane (25 mg/m2 to 70 mg/m2) are tolerated better and are one of the possible approaches. Another possible therapeutic procedure is whole-body irradiation. The advantage of extensive irradiation is rapid regression of pain. Interferon-alpha achieves a therapeutic response in some 20% of refractory patients. Finally the author presents some data on transplantation of bone marrow in patients with multiple myeloma.
Adam
Z
Z
II. interní klinika Fakultní nemocnice Brno-Bohunice.
D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000532:radiotherapy / Q000628:therapy*
D016898:Interferon-alpha; D008558:Melphalan
Terapie refrakterního mnohocetného myelomu (cást II.) Terapie vysokými dávkami alkylacních cytostatik, radioterapie, prínos interferonu a transplantace kostní drenĕ.